Sickle Cell Anemia Screening and Prevention in Northern Israel

This study has been completed.
Ministry of Health, Israel
Information provided by (Responsible Party):
Dr Koren Ariel, HaEmek Medical Center, Israel Identifier:
First received: August 14, 2008
Last updated: August 30, 2015
Last verified: August 2015

Since 1987, a screening for β Thalassemia in pregnant women is carried on in northern Israel, and from 1999 all the samples were tested also for Hgb S, Hgb C, Hgb D, Hgb O Arab and others.

In this study, the investigators intend to summarize the results of this preventive program aiming to detect couples at risk for having offspring with Thalassemia or SCA, the compliance regard to genetic counseling and prenatal diagnosis and the incidence of new affected babies born.

Condition Intervention
Sickle Cell Anemia
Other: Observational

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Summary of the Data From the Prevention Programme for Hemoglobinopathies in Northern Israel

Resource links provided by NLM:

Further study details as provided by HaEmek Medical Center, Israel:

Primary Outcome Measures:
  • Number of carriers detected [ Time Frame: End of study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Couples referred for prenatal diagnosis [ Time Frame: End of study ] [ Designated as safety issue: No ]

Enrollment: 69
Study Start Date: May 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Thalassemia Minor carriers
Other: Observational
Summary of data
Sickle cell carriers
Other: Observational
Summary of data


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The program for prevention of hemoglobinopathies in Northern Israel, instituted since 1987, covered the northern part of Israel, including the Jezreel valley, the Nazareth area, the upper Galilee, the Hula valley and the northern part of the seashore region7. The overall population in this region is about a million inhabitants with about 50 % of Arab population, and a significant percentage of them from Bedouin origin, a population that at least partially is of African origin.

Inclusion Criteria: All pregnant women tested and their husband in those cases that the woman test revealed abnormal hemoglobin.

Exclusion Criteria: No exclusion criteria.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00735488

Pediatric Hematology Unit - Ha'Emek Medical Center
Afula, Israel, 18101
Sponsors and Collaborators
HaEmek Medical Center, Israel
Ministry of Health, Israel
Principal Investigator: Ariel Koren, MD Pediatric Hematology Unit - Ha'Emek Medical Center - Afula - 18101 - Israel
  More Information

No publications provided

Responsible Party: Dr Koren Ariel, Head of Pediatric Hematology Unit and Pediatric Dpt B, HaEmek Medical Center, Israel Identifier: NCT00735488     History of Changes
Other Study ID Numbers: 0011-08-EMC
Study First Received: August 14, 2008
Last Updated: August 30, 2015
Health Authority: Israel: Ministry of Health

Keywords provided by HaEmek Medical Center, Israel:
Sickle cell anemia
Carrier detection
Prenatal Diagnosis
Genetic counseling

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn
Hematologic Diseases
Hemoglobinopathies processed this record on November 27, 2015